SBIR-STTR Award

Active Disposable Cap for Endoscope Tip Stabilization and Complete Visualization and Dissection of Serrated Sessile Polyps
Award last edited on: 2/19/2024

Sponsored Program
SBIR
Awarding Agency
NIH : NIDDK
Total Award Amount
$4,951,806
Award Phase
2
Solicitation Topic Code
847
Principal Investigator
Maureen L Mulvihill

Company Information

Actuated Medical Inc (AKA: PRII~Piezo Resonance Innovations Inc)

310 Rolling Ridge Drive
Bellefonte, PA 16823
   (814) 355-0003
   info@actuatedmedical.com
   www.actuatedmedical.com
Location: Single
Congr. District: 15
County: Centre

Phase I

Contract Number: 1R44DK117813-01A1
Start Date: 8/7/2018    Completed: 4/30/2019
Phase I year
2018
Phase I Amount
$265,113
The SBIR Fast-track develops, tests, and commercializes the "˜Active Disposable Cap for Endoscope (ACE) Tip Stabilization and Complete Visualization and Dissection of Serrated Sessile Polyps.' The disposable system includes a distal-connecting cap, allowing a clinician to manipulate tissue and perform targeted aspiration during complex polypectomies using proximal controls, without occupying the endoscopic working channel. Public Health Problem: In the U.S., colorectal cancer is one of the most deadly and costly forms of cancer. Current endoscopy tools are inadequate to consistently enable full resection of colon polyps. Even polyps <10 mm have an estimated 29% incomplete resection rate. Larger (>2cm), complicated polyps (e.g., flat sessile lesions) are particularly prone to recurrence and malignancy, impacting patient care and healthcare costs. Rates of standard piecemeal resection, which is significantly associated with residual polyp, increases from 3% at <2cm to 85% for polyps >2cm. Endoscopic submucosal dissection (ESD) enabled en bloc removal of >2 cm polyps in 84-95% of cases, and showed a 0-2% tumor recurrence, in one Japanese study, though this expertise is limited outside this geographic region. In nearly all other countries, rates of en bloc ESD are well below 50% - and ESD procedures take over 100 minutes compared to 20-50 minutes for piecemeal resection. Open surgical resection further increases risks and costs. The goal of this proposed project is allowing a safe and effective en bloc ESD with full lesion removal to be performed rapidly. Phase I Hypothesis. ACE enables en bloc resection of large simulated polyps and acceptable forces on tissues in vitro, and demonstrates improved working capabilities in vivo with any damage to porcine colon limited to the mucosa. Aim 1 - ACE demonstrates improved polypectomy functionality and demonstrates safety from perforation in bench models. Acceptance Criteria: Favorable clinician response on ACE capabilities and performance based on 10-point Likert scale, and ≥75% (18/24) successful en bloc resections of ≥ 2cm, difficult lesions in vitro. Aim 2 - Confirm safety and efficacy feasibility of ACE in pilot preclinical study. Acceptance Criteria: Pilot in vivo study (N=3) successfully achieves simulated ≥2cm polyp removal en bloc in porcine model with no significant colon damage or adverse events at up to 72-hours post-procedure. Phase II Hypothesis. ACE is safe and effective for improving endoscopic access and stability, and complete lesion removal, during complex polypectomies in the colon. Aim 3 - Verification and validation to support regulatory submissions. Acceptance Criteria: Pass acceptance criteria on each individual test. Acceptance criteria are set on an individual test basis using a risk- based approach. Aim 4 - Demonstrate faster en bloc resection and same or better safety with ACE versus endoscope-only. Submission of the De Novo premarket application to the FDA. Acceptance Criteria: ACE reduces en bloc resection procedure time relative to endoscope-only resection (N=16; p<0.05, ß<0.1) with the same or less visual and histological mucosal damage and no adverse events. FDA De Novo submission.

Public Health Relevance Statement:


Project narrative:
Relevance - At least 3.4 million endoscopic polyp removal (polypectomy) procedures are performed in the U.S. annually as part of a regimen for prevention of colorectal cancer, one of the leading causes of cancer- related deaths. In the case of large polyps (≥2cm), the limitations of the endoscope and accessory tools within the narrow operational field often necessitate either less-desirable piecemeal resection, increasing the risk of incomplete removal, or open surgical resection referral. The proposed Active Cap System for Endoscopes is a disposable accessory device that enables physician-controlled tissue manipulation and aspiration during polypectomy without occupying the working channel of the endoscope. The goal is to safely reduce procedural time and the number of open surgery referrals for small or large polyps, while ensuring complete polyp removal.

Project Terms:
Awareness; Malignant Neoplasms; neoplasm/cancer; malignancy; Malignant Tumor; Cancers; Clinical Research; Clinical Study; Colon; Colonic Polyps; colon polyp; Colonoscopy; Cessation of life; Death; Dissection; Endoscopes; Endoscopy; endoscopic imaging; Fingers; Patient Care; Patient Care Delivery; Geographic Locations; geographic site; Geographical Location; Geographic Region; Geographic Area; Goals; Grant; Hand; In Vitro; Influenza; influenza infection; flu infection; Grippe; Japanese Population; Japanese; Marketing; Medical Device; Motion; Mucous Membrane; Mucosal Tissue; Mucosa; Physicians; Polyps; Privatization; Public Health; Recurrence; Recurrent; Risk; Safety; Sales; Family suidae; suid; porcine; Swine; Suidae; Pigs; Technology; Testing; Time; Tissues; Body Tissues; Health Care Costs; Healthcare Costs; Health Costs; Visualization; Imagery; base; improved; Procedures; Distal; Residual; Residual state; Phase; Histologically; Histologic; Medical; Ensure; Lesion; Visual; Individual; Funding; prevent colorectal cancer; colo-rectal cancer prevention; CRC prevention; colorectal cancer prevention; Letters; tool; Mechanics; mechanical; Hour; Complex; System; Country; Polypectomy; PLYPCMY; Operative Surgical Procedures; surgery; Surgical Procedure; Surgical Interventions; Surgical; Operative Procedures; Perforation; Colorectal; colorectum; colo-rectal; Colon or Rectum; experience; Performance; Devices; Excision; resection; Surgical Removal; Removal; Extirpation; Abscission; Modeling; response; Adverse event; Adverse Experience; cancer diagnosis; Effectiveness; Sessile Lesion; Address; Pre-Clinical Model; Preclinical Models; in vivo; Cancer Cause; Cancer Etiology; Small Business Innovation Research; SBIR; Small Business Innovation Research Grant; developmental; Development; Colo-rectal Cancer; Colorectal Cancer; pre-clinical study; preclinical study; cost; designing; design; Outcome; innovative; innovate; innovation; commercialization; tumor; verification and validation; flexible; flexibility; Regimen; operation; care costs

Phase II

Contract Number: 4R44DK117813-02
Start Date: 8/7/2018    Completed: 1/31/2021
Phase II year
2019
(last award dollars: 2023)
Phase II Amount
$4,686,693

The SBIR Fast-track develops, tests, and commercializes the "˜Active Disposable Cap for Endoscope (ACE) Tip Stabilization and Complete Visualization and Dissection of Serrated Sessile Polyps.' The disposable system includes a distal-connecting cap, allowing a clinician to manipulate tissue and perform targeted aspiration during complex polypectomies using proximal controls, without occupying the endoscopic working channel. Public Health Problem: In the U.S., colorectal cancer is one of the most deadly and costly forms of cancer. Current endoscopy tools are inadequate to consistently enable full resection of colon polyps. Even polyps <10 mm have an estimated 29% incomplete resection rate. Larger (>2cm), complicated polyps (e.g., flat sessile lesions) are particularly prone to recurrence and malignancy, impacting patient care and healthcare costs. Rates of standard piecemeal resection, which is significantly associated with residual polyp, increases from 3% at <2cm to 85% for polyps >2cm. Endoscopic submucosal dissection (ESD) enabled en bloc removal of >2 cm polyps in 84-95% of cases, and showed a 0-2% tumor recurrence, in one Japanese study, though this expertise is limited outside this geographic region. In nearly all other countries, rates of en bloc ESD are well below 50% - and ESD procedures take over 100 minutes compared to 20-50 minutes for piecemeal resection. Open surgical resection further increases risks and costs. The goal of this proposed project is allowing a safe and effective en bloc ESD with full lesion removal to be performed rapidly. Phase I Hypothesis. ACE enables en bloc resection of large simulated polyps and acceptable forces on tissues in vitro, and demonstrates improved working capabilities in vivo with any damage to porcine colon limited to the mucosa. Aim 1 - ACE demonstrates improved polypectomy functionality and demonstrates safety from perforation in bench models. Acceptance Criteria: Favorable clinician response on ACE capabilities and performance based on 10-point Likert scale, and ≥75% (18/24) successful en bloc resections of ≥ 2cm, difficult lesions in vitro. Aim 2 - Confirm safety and efficacy feasibility of ACE in pilot preclinical study. Acceptance Criteria: Pilot in vivo study (N=3) successfully achieves simulated ≥2cm polyp removal en bloc in porcine model with no significant colon damage or adverse events at up to 72-hours post-procedure. Phase II Hypothesis. ACE is safe and effective for improving endoscopic access and stability, and complete lesion removal, during complex polypectomies in the colon. Aim 3 - Verification and validation to support regulatory submissions. Acceptance Criteria: Pass acceptance criteria on each individual test. Acceptance criteria are set on an individual test basis using a risk- based approach. Aim 4 - Demonstrate faster en bloc resection and same or better safety with ACE versus endoscope-only. Submission of the De Novo premarket application to the FDA. Acceptance Criteria: ACE reduces en bloc resection procedure time relative to endoscope-only resection (N=16; p<0.05, ß<0.1) with the same or less visual and histological mucosal damage and no adverse events. FDA De Novo submission.

Public Health Relevance Statement:


Project narrative:
Relevance - At least 3.4 million endoscopic polyp removal (polypectomy) procedures are performed in the U.S. annually as part of a regimen for prevention of colorectal cancer, one of the leading causes of cancer- related deaths. In the case of large polyps (≥2cm), the limitations of the endoscope and accessory tools within the narrow operational field often necessitate either less-desirable piecemeal resection, increasing the risk of incomplete removal, or open surgical resection referral. The proposed Active Cap System for Endoscopes is a disposable accessory device that enables physician-controlled tissue manipulation and aspiration during polypectomy without occupying the working channel of the endoscope. The goal is to safely reduce procedural time and the number of open surgery referrals for small or large polyps, while ensuring complete polyp removal.

Project Terms:
Awareness; Malignant Neoplasms; neoplasm/cancer; malignancy; Malignant Tumor; Cancers; Clinical Study; Clinical Research; Colon; colon polyp; Colonic Polyps; Colonoscopy; Death; Cessation of life; Dissection; Endoscopes; endoscopic imaging; Endoscopy; Fingers; Patient Care Delivery; Patient Care; geographic site; Geographical Location; Geographic Region; Geographic Area; Geographic Locations; Goals; Grant; Hand; In Vitro; influenza infection; flu infection; Grippe; Influenza; Japanese; Japanese Population; Marketing; Medical Device; Motion; Mucosal Tissue; Mucosa; Mucous Membrane; Physicians; Polyps; Privatization; Public Health; Recurrent; Recurrence; Risk; Safety; Sales; suid; porcine; Swine; Suidae; Pigs; Family suidae; Technology; Testing; Time; Body Tissues; Tissues; Healthcare Costs; Health Costs; Health Care Costs; Imagery; Visualization; base; improved; Procedures; Distal; Residual state; Residual; Phase; Histologic; Histologically; Medical; Ensure; Lesion; Visual; Individual; Funding; colorectal cancer prevention; prevent colorectal cancer; prevent colo-rectal cancer; colo-rectal cancer prevention; CRC prevention; Letters; tool; Mechanics; mechanical; Hour; Complex; System; Country; Polypectomy; PLYPCMY; Operative Surgical Procedures; surgery; Surgical Procedure; Surgical Interventions; Surgical; Operative Procedures; Perforation; Colorectal; colorectum; colo-rectal; Colon or Rectum; experience; Performance; Devices; Excision; resection; Surgical Removal; Removal; Extirpation; Abscission; Modeling; response; Adverse event; Adverse Experience; cancer diagnosis; Effectiveness; Sessile Lesion; Address; Pre-Clinical Model; Preclinical Models; in vivo; Cancer Etiology; Cancer Cause; Small Business Innovation Research Grant; Small Business Innovation Research; SBIR; Development; developmental; Colorectal Cancer; Colo-rectal Cancer; preclinical study; pre-clinical study; cost; design; designing; Outcome; innovation; innovative; innovate; commercialization; tumor; verification and validation; flexibility; flexible; Regimen; operation; care costs